Imidazo[1,2-B][1,2,4]triazines as c-Met inhibitors

Patent metadata

Field	Value
Publication number	US-9988387-B2
Application number	US-201514918879-A
Country	US
Kind code	B2
Filing date	Oct 21, 2015
Priority date	Feb 3, 2010
Publication date	Jun 5, 2018
Grant date	Jun 5, 2018

Abstract

The present invention relates to imidazo[1,2-b][1,2,4]triazines that are inhibitors of c-Met and are useful in the treatment of c-Met associated diseases including cancer.

First claim

What is claimed is:

1. A method of treating gastric cancer, cancer of the kidney, liver cancer, lung cancer, or glioblastoma in a patient, wherein said cancer is associated with dysregulation of the HGF/c-MET signaling pathway, comprising administering to said patient a therapeutically effective amount of a compound, selected from
2-chloro-N-[(1S)-1-(5-methyl-1,2,4-oxadiazol-3-yl)ethyl]-4-[7-(quinolin-6-ylmethyl)imidazo[1,2-b][1,2,4]triazin-2-yl]benzamide;
or a pharmaceutically acceptable salt of any of the aforementioned.

2. A method of treating gastric cancer, cancer of the kidney, liver cancer, lung cancer, or glioblastoma in a patient comprising administering to said patient a therapeutically effective amount of a compound selected from
2-chloro-N-[(1S)-1-(5-methyl-1,2,4-oxadiazol-3-yl)ethyl]-4-[7-(quinolin-6-ylmethyl)imidazo[1,2-b][1,2,4]triazin-2-yl]benzamide;
or a pharmaceutically acceptable salt of any of the aforementioned.

3. The method of claim 1 , wherein said cancer is gastric cancer.

4. The method of claim 1 , wherein said cancer is cancer of the kidney.

5. The method of claim 1 , wherein said cancer is liver cancer.

6. The method of claim 1 , wherein said cancer is lung cancer.

7. The method of claim 1 , wherein said cancer is glioblastoma.

8. The method of claim 2 , wherein said cancer is gastric cancer.

9. The method of claim 2 , wherein said cancer is cancer of the kidney.

10. The method of claim 2 , wherein said cancer is liver cancer.

11. The method of claim 2 , wherein said cancer is lung cancer.

12. The method of claim 2 , wherein said cancer is glioblastoma.

Assignees

• Incyte Holdings Corp
• Incyte Corp

Inventors

• Zhuo Jincong
• He Chunhong
• Yao Wenqing

Classifications

• C07D487/04 Primary

  Ortho-condensed systems · CPC title

• A61K31/53

  having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine (melarsoprol A61K31/555 {; with four nitrogen atoms A61K31/495}) · CPC title

• C07D403/04

  directly linked by a ring-member-to-ring-member bond · CPC title

• C07D403/06

  linked by a carbon chain containing only aliphatic carbon atoms · CPC title

• A61P35/00

  Antineoplastic agents · CPC title